drugset / Trial / NCT03922204
A Study of Bispecific Antibody MCLA-145 in Patients With Advanced or Metastatic Malignancies
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is an open-label, non-randomized, Phase 1 study to determine the safety, tolerability, and preliminary efficacy of MCLA-145 in adult patients with advanced metastatic solid tumors or B-cell lymphomas. The study will be conducted in 2 parts.
Timeline
- Start
- 2019-05-08
- Primary completion
- 2024-11-07
- Completion
- 2024-11-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | MCLA-145 | Monoclonal antibody | — | Intravenous |
| Subject | Pembrolizumab | Monoclonal antibody | 200 mg | — |